India · Delayed Price · Currency is INR Aarti Drugs Statistics
Total Valuation
Aarti Drugs has a market cap or net worth of INR 34.21 billion. The enterprise value is 39.70 billion.
| Market Cap | 34.21B |
| Enterprise Value | 39.70B |
Important Dates
The next estimated earnings date is Friday, January 23, 2026.
| Earnings Date | Jan 23, 2026 |
| Ex-Dividend Date | Feb 4, 2025 |
Share Statistics
Aarti Drugs has 91.27 million shares outstanding. The number of shares has decreased by -5.05% in one year.
| Current Share Class | 91.27M |
| Shares Outstanding | 91.27M |
| Shares Change (YoY) | -5.05% |
| Shares Change (QoQ) | +8.32% |
| Owned by Insiders (%) | 48.07% |
| Owned by Institutions (%) | 19.04% |
| Float | 34.68M |
Valuation Ratios
The trailing PE ratio is 16.38 and the forward PE ratio is 15.08. Aarti Drugs's PEG ratio is 0.66.
| PE Ratio | 16.38 |
| Forward PE | 15.08 |
| PS Ratio | 1.38 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 2.35 |
| P/FCF Ratio | 72.70 |
| P/OCF Ratio | 14.95 |
| PEG Ratio | 0.66 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.82, with an EV/FCF ratio of 84.37.
| EV / Earnings | 19.94 |
| EV / Sales | 1.60 |
| EV / EBITDA | 12.82 |
| EV / EBIT | 15.78 |
| EV / FCF | 84.37 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.39.
| Current Ratio | 1.68 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 1.85 |
| Debt / FCF | 12.19 |
| Interest Coverage | 7.29 |
Financial Efficiency
Return on equity (ROE) is 14.49% and return on invested capital (ROIC) is 10.78%.
| Return on Equity (ROE) | 14.49% |
| Return on Assets (ROA) | 6.24% |
| Return on Invested Capital (ROIC) | 10.78% |
| Return on Capital Employed (ROCE) | 13.75% |
| Weighted Average Cost of Capital (WACC) | 5.24% |
| Revenue Per Employee | 19.29M |
| Profits Per Employee | 1.55M |
| Employee Count | 1,284 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 3.39 |
Taxes
In the past 12 months, Aarti Drugs has paid 344.44 million in taxes.
| Income Tax | 344.44M |
| Effective Tax Rate | 14.76% |
Stock Price Statistics
The stock price has decreased by -11.99% in the last 52 weeks. The beta is 0.18, so Aarti Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -11.99% |
| 50-Day Moving Average | 410.48 |
| 200-Day Moving Average | 453.48 |
| Relative Strength Index (RSI) | 33.24 |
| Average Volume (20 Days) | 8,717 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aarti Drugs had revenue of INR 24.77 billion and earned 1.99 billion in profits. Earnings per share was 22.89.
| Revenue | 24.77B |
| Gross Profit | 8.85B |
| Operating Income | 2.52B |
| Pretax Income | 2.33B |
| Net Income | 1.99B |
| EBITDA | 3.08B |
| EBIT | 2.52B |
| Earnings Per Share (EPS) | 22.89 |
Balance Sheet
The company has 245.40 million in cash and 5.73 billion in debt, with a net cash position of -5.49 billion or -60.15 per share.
| Cash & Cash Equivalents | 245.40M |
| Total Debt | 5.73B |
| Net Cash | -5.49B |
| Net Cash Per Share | -60.15 |
| Equity (Book Value) | 14.69B |
| Book Value Per Share | 148.52 |
| Working Capital | 5.30B |
Cash Flow
In the last 12 months, operating cash flow was 2.29 billion and capital expenditures -1.82 billion, giving a free cash flow of 470.62 million.
| Operating Cash Flow | 2.29B |
| Capital Expenditures | -1.82B |
| Free Cash Flow | 470.62M |
| FCF Per Share | 5.16 |
Margins
Gross margin is 35.75%, with operating and profit margins of 10.16% and 8.04%.
| Gross Margin | 35.75% |
| Operating Margin | 10.16% |
| Pretax Margin | 9.43% |
| Profit Margin | 8.04% |
| EBITDA Margin | 12.46% |
| EBIT Margin | 10.16% |
| FCF Margin | 1.90% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.27%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.55% |
| Buyback Yield | 5.05% |
| Shareholder Yield | 5.32% |
| Earnings Yield | 5.82% |
| FCF Yield | 1.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 30, 2020. It was a forward split with a ratio of 4.
| Last Split Date | Sep 30, 2020 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |